Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Joshua F ZeidnerBenjamin G VincentAnastasia IvanovaDominic MooreKaren P McKinnonAlec D WilkinsonRupkatha MukhopadhyayFrancesco MazziottaHanna A KnausMatthew C FosterCatherine C CoombsKatarzyna JamiesonHendrik Van DeventerJonathan A WebsterGabrielle T PrinceAmy E DeZernB Douglas SmithMark J LevisNathan D MontgomeryLeo LuznikJonathan S SerodyIvana GojoPublished in: Blood cancer discovery (2021)
Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage regimen. Further study of pembrolizumab and other immune-checkpoint blockade strategies after cytotoxic chemotherapy is warranted in AML.See related commentary by Wei et al., p. 551. This article is highlighted in the In This Issue feature, p. 549.
Keyphrases
- acute myeloid leukemia
- high dose
- advanced non small cell lung cancer
- allogeneic hematopoietic stem cell transplantation
- low dose
- stem cell transplantation
- machine learning
- squamous cell carcinoma
- locally advanced
- epidermal growth factor receptor
- clinical trial
- open label
- radiation therapy
- acute lymphoblastic leukemia
- anti inflammatory